Ventyx Biosciences (Ventyx Biosciences) Forward PE Ratio : 0.00 (As of May. 21, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ventyx Biosciences Forward PE Ratio?

Ventyx Biosciences's Forward PE Ratio for today is 0.00.

Ventyx Biosciences's PE Ratio without NRI for today is 0.00.

Ventyx Biosciences's PE Ratio for today is 0.00.

Ventyx Biosciences Forward PE Ratio Historical Data

The historical data trend for Ventyx Biosciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ventyx Biosciences Forward PE Ratio Chart

Ventyx Biosciences Annual Data

Trend

Forward PE Ratio

Ventyx Biosciences Quarterly Data

Forward PE Ratio

Competitive Comparison of Ventyx Biosciences's Forward PE Ratio

For the Biotechnology subindustry, Ventyx Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ventyx Biosciences's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ventyx Biosciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Ventyx Biosciences's Forward PE Ratio falls into.

Ventyx Biosciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Ventyx Biosciences (NAS:VTYX) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Ventyx Biosciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Ventyx Biosciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Ventyx Biosciences (Ventyx Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ventyx Biosciences Inc (NAS:VTYX) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

662 Encinitas Boulevard, Suite 250, Encinitas, CA, USA, 92024

Website

https://www.ventyxbio.com

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Executives

Raju Mohan	director, officer: Chief Executive Officer	C/O VENTYX BIOSCINECES, INC., 332 ENCINITAS BLVD., SUITE 200, ENCINITAS CA 92024
John Nuss	officer: Chief Scientific Officer	C/O VENTYX BIOSCIENCES, INC., 332 ENCINITAS BLVD. SUITE 200, ENCINITAS CA 92024
Christopher W Krueger	officer: Chief Business Officer	C/O ARDEA BIOSCIENCES INC, 2131 PALOMAR AIRPORT ROAD SUITE 300, CARLSBAD CA 92011
Nsv Partners Iii Lp	10 percent owner	500 WEST PUTNAM AVE, SUITE 400, GREENWICH CT 06830
Somu Subramaniam	director, 10 percent owner	C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Martin Auster	officer: Chief Financial Officer	C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
William J. Sandborn	officer: See Remarks	C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
Sheila Gujrathi	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
William Richard White	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Onaiza Cadoret-manier	director	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Allison Hulme	director	C/O SOPHIRIS BIO INC., 1258 PROSPECT ST, LA JOLLA CA 92037
Venbio Global Strategic Fund Iii, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston	director, 10 percent owner	200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116